Matisse Pharmaceuticals B.V. focuses on developing innovative therapeutic solutions, particularly in the field of oncology. The company employs advanced drug delivery systems that enhance the efficacy and safety of its pharmaceutical products. Their proprietary technologies aim to optimize the pharmacokinetics and bioavailability of active compounds, ensuring that treatments are both effective and well-tolerated by patients. This commitment to innovation is reflected in their robust pipeline, which includes several promising candidates designed to address unmet medical needs in cancer treatment.

In addition to their drug delivery systems, Matisse Pharmaceuticals emphasizes the importance of scientific research and collaboration in their development processes. The company leverages cutting-edge methodologies in drug formulation and testing, which are supported by a strong foundation in molecular biology and pharmacology. By integrating these scientific principles with their technological advancements, Matisse Pharmaceuticals aims to accelerate the development of new therapies and improve patient outcomes in oncology.

Netherlands

Matisse Pharmaceuticals BV was founded in 2014 in Geleen, the Netherlands. Matisse targets life-threatening inflammation by neutralizing cytotoxic components of the inflammatory system. Its main development program is the development of a medicine to fight sepsis and septic shock, which is currently in clinical phase.

Matisse Pharmaceuticals B.V.

Company Details